William Blair Issues Negative Outlook for AXSM Earnings

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Equities researchers at William Blair decreased their Q1 2025 earnings per share estimates for shares of Axsome Therapeutics in a research note issued to investors on Tuesday, February 18th. William Blair analyst M. Minter now anticipates that the company will post earnings per share of ($1.46) for the quarter, down from their previous estimate of ($0.95). William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($2.26) per share. William Blair also issued estimates for Axsome Therapeutics’ Q2 2025 earnings at ($1.28) EPS, Q3 2025 earnings at ($0.92) EPS, Q4 2025 earnings at ($0.56) EPS, FY2025 earnings at ($4.23) EPS, Q1 2026 earnings at ($0.39) EPS, Q2 2026 earnings at $0.22 EPS, Q3 2026 earnings at $0.93 EPS, Q4 2026 earnings at $1.62 EPS, FY2026 earnings at $2.38 EPS and FY2027 earnings at $13.85 EPS.

Other equities research analysts have also issued research reports about the stock. Bank of America increased their price objective on shares of Axsome Therapeutics from $143.00 to $167.00 and gave the stock a “buy” rating in a research report on Tuesday, February 11th. Royal Bank of Canada increased their price target on Axsome Therapeutics from $143.00 to $192.00 and gave the company an “outperform” rating in a report on Wednesday. Mizuho boosted their price objective on Axsome Therapeutics from $137.00 to $195.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 11th. Leerink Partners increased their target price on Axsome Therapeutics from $110.00 to $150.00 and gave the company an “outperform” rating in a research note on Monday, February 10th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $153.00 target price on shares of Axsome Therapeutics in a report on Wednesday. One investment analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $155.47.

Axsome Therapeutics Trading Up 1.7 %

AXSM opened at $129.15 on Friday. The company has a debt-to-equity ratio of 3.22, a current ratio of 2.11 and a quick ratio of 2.37. Axsome Therapeutics has a 1 year low of $64.11 and a 1 year high of $134.18. The firm has a 50 day moving average price of $100.34 and a 200 day moving average price of $94.46.

Axsome Therapeutics (NASDAQ:AXSM) last released its quarterly earnings data on Tuesday, February 18th. The company reported ($0.96) EPS for the quarter, topping analysts’ consensus estimates of ($0.97) by $0.01. Axsome Therapeutics had a negative return on equity of 223.51% and a negative net margin of 74.47%. The company had revenue of $118.77 million for the quarter, compared to the consensus estimate of $117.83 million.

Insider Activity at Axsome Therapeutics

In other news, CFO Nick Pizzie sold 3,000 shares of the business’s stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $131.07, for a total value of $393,210.00. Following the completion of the sale, the chief financial officer now owns 42,187 shares of the company’s stock, valued at approximately $5,529,450.09. The trade was a 6.64 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 22.40% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Axsome Therapeutics

Several large investors have recently modified their holdings of AXSM. Raiffeisen Bank International AG bought a new stake in Axsome Therapeutics in the fourth quarter valued at about $51,000. Assetmark Inc. acquired a new position in shares of Axsome Therapeutics in the 4th quarter worth approximately $52,000. R Squared Ltd bought a new stake in shares of Axsome Therapeutics in the 4th quarter valued at approximately $64,000. Aquatic Capital Management LLC acquired a new stake in shares of Axsome Therapeutics during the 4th quarter valued at approximately $76,000. Finally, GF Fund Management CO. LTD. bought a new position in Axsome Therapeutics during the fourth quarter worth $86,000. Institutional investors own 81.49% of the company’s stock.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.